Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zerlasiran - Silence Therapeutics

Next Previous
X
Search
Drug Profile

Zerlasiran - Silence Therapeutics

Alternative Names: SLN-360

Latest Information Update: 09 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Silence Therapeutics
  • Class Amino sugars; Antihyperlipidaemics; Cardiovascular therapies; Small interfering RNA
  • Mechanism of Action Apolipoprotein A inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cardiovascular disorders
  • Phase I Hyperlipidaemia
  • No development reported Dyslipidaemias

Most Recent Events

  • 01 Jul 2024 Silence Therapeutics completes a phase II ALPACAR-360 trial in Cardiovascular disorders in Australia, Spain, United Kingdom, Denmark, Netherlands, Czech Republic, South Africa and Slovakia (EudraCT2022-001876-32) (NCT05537571)
  • 20 Jun 2024 Efficacy data from the phase-II ALPACAR-360 trial in Cardiovascular disorders released by Silence Therapeutics
  • 20 Jun 2024 Silence Therapeutics plans a phase III trial for Cardiovascular disorders (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top